Skip to main content
Year archive

OPKO Health Inc. — 2024 filings

All 206 regulatory filings released by OPKO Health Inc. (OPK) in 2024, sourced directly from the official regulator.

206 Filings
2024 Period
2024 filings (206)
Filing Released Lang
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIE-Phillip Frost, M.D., ET AL
Director's Dealing
2024-12-15 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIE-Phillip Frost, M.D., ET AL
Regulatory Filings
2024-12-15 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES -Phillip Frost, M.D., ET AL
Director's Dealing
2024-12-12 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES -Phillip Frost, M.D., ET AL
Report Publication Announcement
2024-12-12 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost
Director's Dealing
2024-11-30 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost
Report Publication Announcement
2024-11-30 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-11-23 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Report Publication Announcement
2024-11-23 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-11-21 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-11-21 English
SCHEDULE 13D/A-company's holdings in GeneDx Holdings, Corp
Major Shareholding Notification
2024-11-21 English
SCHEDULE 13D/A-company's holdings in GeneDx Holdings, Corp
Major Shareholding Notification
2024-11-21 English
OPKO Health to participate in the Piper Sandler 36th annual healthcare conference
Report Publication Announcement
2024-11-20 English
OPKO Health to participate in the Piper Sandler 36th annual healthcare conference
Report Publication Announcement
2024-11-20 English
Schedule 13D/A-Phillip Frost, M.D
Major Shareholding Notification
2024-11-16 English
Schedule 13D/A-Phillip Frost, M.D
Regulatory Filings
2024-11-16 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-11-16 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Report Publication Announcement
2024-11-16 English
SCHEDULE 13D/A-company's holdings in GeneDx Holdings, Corp
Major Shareholding Notification
2024-11-09 English
SCHEDULE 13D/A-company's holdings in GeneDx Holdings, Corp
Regulatory Filings
2024-11-09 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-11-09 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Report Publication Announcement
2024-11-09 English
FORM 10-Q-For the quarterly period ended September 30, 2024
Interim / Quarterly Report Q3 2024
2024-11-08 English
FORM 10-Q-For the quarterly period ended September 30, 2024
Report Publication Announcement Q3 2024
2024-11-08 English
8K-OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results
Earnings Release Q3 2024
2024-11-08 English
8K-OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results
Report Publication Announcement
2024-11-08 English
OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024
Earnings Release 9M 2024
2024-10-30 English
OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024
Report Publication Announcement
2024-10-30 English
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
Regulatory Filings
2024-10-07 English
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
Report Publication Announcement
2024-10-07 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-09-28 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-09-28 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-09-28 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-09-28 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-09-27 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-09-27 English
Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
Regulatory Filings
2024-09-25 English
Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
Report Publication Announcement
2024-09-25 English
OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development
Board/Management Information
2024-09-23 English
OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development
Regulatory Filings
2024-09-23 English
SCHEDULE 13D/A
Major Shareholding Notification
2024-09-18 English
SCHEDULE 13D/A
Major Shareholding Notification
2024-09-18 English
Form 8-K-Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
Delisting Announcement
2024-09-16 English
Form 8-K-Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
Regulatory Filings
2024-09-16 English
Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
M&A Activity
2024-09-16 English
Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
Report Publication Announcement
2024-09-16 English
Schedule 14A, Amendment No.1 - amendment to the proxy statement of OPKO filed on February 29, 2024
Proxy Solicitation & Information Statement
2024-08-31 English
Schedule 14A, Amendment No.1 - amendment to the proxy statement of OPKO filed on February 29, 2024
Proxy Solicitation & Information Statement
2024-08-31 English
SCHEDULE 13D/A- Frost Gamma Investments Trust
Major Shareholding Notification
2024-08-30 English
SCHEDULE 13D/A- Frost Gamma Investments Trust
Report Publication Announcement
2024-08-30 English
SCHEDULE 13D/A-company's holdings in GeneDx Holdings, Corp
Major Shareholding Notification
2024-08-24 English
SCHEDULE 13D/A-company's holdings in GeneDx Holdings, Corp
Report Publication Announcement
2024-08-24 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES AT GeneDx Holdings Corp
Director's Dealing
2024-08-20 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES AT GeneDx Holdings Corp
Director's Dealing
2024-08-20 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-OPKO Health, Inc
Director's Dealing
2024-08-14 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-OPKO Health, Inc
Report Publication Announcement
2024-08-14 English
SCHEDULE 13D/A-GeneDx Holdings, Corp
Major Shareholding Notification
2024-08-13 English
SCHEDULE 13D/A-GeneDx Holdings, Corp
Regulatory Filings
2024-08-13 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-OPKO Health, Inc
Director's Dealing
2024-08-09 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-OPKO Health, Inc
Director's Dealing
2024-08-09 English
Form 10-Q- For the quarterly period ended June 30, 2024.
Interim / Quarterly Report Q2 2024
2024-08-07 English
Form 10-Q- For the quarterly period ended June 30, 2024.
Report Publication Announcement
2024-08-07 English
Form 8-K-Second Quarter 2024 Business Highlights and Financial Results
Earnings Release Q2 2024
2024-08-07 English
Form 8-K-Second Quarter 2024 Business Highlights and Financial Results
Report Publication Announcement
2024-08-07 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES AT GeneDx Holdings Corp
Director's Dealing
2024-08-03 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES AT GeneDx Holdings Corp
Report Publication Announcement
2024-08-03 English
OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024
Earnings Release Q2 2024
2024-08-02 English
OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024
Report Publication Announcement
2024-08-02 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES AT GeneDx Holdings Corp
Director's Dealing
2024-08-01 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES AT GeneDx Holdings Corp
Report Publication Announcement
2024-08-01 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Elias Zerhouni, M.D.
Director's Dealing
2024-07-28 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Elias Zerhouni, M.D.
Report Publication Announcement
2024-07-28 English
CHANGES IN BENEFICIAL OWNERSHIP-FORM 4-Steven D. Rubin
Director's Dealing
2024-07-28 English
CHANGES IN BENEFICIAL OWNERSHIP-FORM 4-Steven D. Rubin
Director's Dealing
2024-07-28 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF F SECURITIES-Gary J. Nabel, M.D., Ph.D
Director's Dealing
2024-07-28 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF F SECURITIES-Gary J. Nabel, M.D., Ph.D
Regulatory Filings
2024-07-28 English
CHANGES IN BENEFICIAL OWNERSHIP-FORM 4-Adam Logal
Director's Dealing
2024-07-28 English
CHANGES IN BENEFICIAL OWNERSHIP-FORM 4-Adam Logal
Report Publication Announcement
2024-07-28 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Jane H. Hsiao, Ph.D.
Director's Dealing
2024-07-28 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Jane H. Hsiao, Ph.D.
Director's Dealing
2024-07-28 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-07-28 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Report Publication Announcement
2024-07-28 English
FORM 4- Updating the company's holdings in GeneDx Holdings Corp. [ WGS ]
Director's Dealing
2024-07-28 English
FORM 4- Updating the company's holdings in GeneDx Holdings Corp. [ WGS ]
Report Publication Announcement
2024-07-28 English
FORM 8-K-Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Remuneration Information
2024-07-28 English
FORM 8-K-Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Remuneration Information
2024-07-28 English
Updating the company's holdings in GeneDx Holdings, Corp
Major Shareholding Notification
2024-07-28 English
Updating the company's holdings in GeneDx Holdings, Corp
Regulatory Filings
2024-07-28 English
Updating the company's holdings in GeneDx Holdings, Corp
Director's Dealing
2024-07-24 English
Updating the company's holdings in GeneDx Holdings, Corp
Report Publication Announcement
2024-07-24 English
Updating the company's holdings in GeneDx Holdings, Corp
Director's Dealing
2024-07-21 English
Updating the company's holdings in GeneDx Holdings, Corp
Report Publication Announcement
2024-07-21 English
Announces $100 Million Share Repurchase Program
Transaction in Own Shares
2024-07-18 English
Announces $100 Million Share Repurchase Program
Report Publication Announcement
2024-07-18 English
OPKO Health and HealthCare Royalty Enter into $250 Million ‎Note Purchase Agreement Secured by NGENLA’s Profit Share ‎Payments‎
Capital/Financing Update
2024-07-17 English
OPKO Health and HealthCare Royalty Enter into $250 Million ‎Note Purchase Agreement Secured by NGENLA’s Profit Share ‎Payments‎
Regulatory Filings
2024-07-17 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-OPKO Health, Inc.
Director's Dealing
2024-07-10 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-OPKO Health, Inc.
Report Publication Announcement
2024-07-10 English
SCHEDULE 13D/A-GeneDx Holdings, Corp
Major Shareholding Notification
2024-07-06 English
SCHEDULE 13D/A-GeneDx Holdings, Corp
Regulatory Filings
2024-07-06 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-OPKO Health, Inc
Director's Dealing
2024-07-04 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-OPKO Health, Inc
Regulatory Filings
2024-07-04 English
Form 144- NOTICE OF PROPOSED SALE OF SECURITIES-GeneDx Holdings
Regulatory Filings
2024-06-29 English
Form 144- NOTICE OF PROPOSED SALE OF SECURITIES-GeneDx Holdings
Regulatory Filings
2024-06-29 English
OPKO Health to Participate in the Jefferies Global Healthcare Conference.
Regulatory Filings
2024-06-01 English
OPKO Health to Participate in the Jefferies Global Healthcare Conference.
Report Publication Announcement
2024-06-01 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET A
Director's Dealing
2024-05-24 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET A
Regulatory Filings
2024-05-24 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-05-18 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Regulatory Filings
2024-05-18 English
FORM 10-Q-For the quarterly period ended March 31, 2024
Interim / Quarterly Report Q1 2024
2024-05-07 English
FORM 10-Q-For the quarterly period ended March 31, 2024
Report Publication Announcement
2024-05-07 English
First Quarter 2024 Business Highlights and Financial Results
Earnings Release Q1 2024
2024-05-07 English
First Quarter 2024 Business Highlights and Financial Results
Report Publication Announcement
2024-05-07 English
to Report First Quarter 2024 Financial Results on May 7, 2024,conference call and live audio webcast on May 7th beginning at 4:30 p.m. Eastern time
Earnings Release Q1 2024
2024-05-04 English
to Report First Quarter 2024 Financial Results on May 7, 2024,conference call and live audio webcast on May 7th beginning at 4:30 p.m. Eastern time
Report Publication Announcement
2024-05-04 English
Form 4- CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Alice Lin-Tsing Yu, M.D., Ph.D.
Earnings Release Q4 2023
2024-03-30 Portuguese
Form 4- CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Alice Lin-Tsing Yu, M.D., Ph.D.
Report Publication Announcement
2024-03-30 English
Form 4- CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Richard C. Pfenniger, Jr.
Director's Dealing
2024-03-30 English
Form 4- CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Richard C. Pfenniger, Jr.
Report Publication Announcement
2024-03-30 English
Form 4- CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- John A.Paganelli
Director's Dealing
2024-03-30 English
Form 4- CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- John A.Paganelli
Report Publication Announcement
2024-03-30 English
Form 4- CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Roger J. Medel, M.D.
Director's Dealing
2024-03-30 English
Form 4- CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Roger J. Medel, M.D.
Report Publication Announcement
2024-03-30 English
Form 4- CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Prem A.Lachman, M.D.
Director's Dealing
2024-03-30 English
Form 4- CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Prem A.Lachman, M.D.
Report Publication Announcement
2024-03-30 English
Form 4- CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Richard. Kranso, Ph.D.
Director's Dealing
2024-03-30 English
Form 4- CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Richard. Kranso, Ph.D.
Report Publication Announcement
2024-03-30 English
FORM 8-K-Results of the Annual General Meeting of Shareholders of the Company held On March 28, 2024
Declaration of Voting Results & Voting Rights Announcements
2024-03-30 English
FORM 8-K-Results of the Annual General Meeting of Shareholders of the Company held On March 28, 2024
Report Publication Announcement
2024-03-30 English
FORM 8-K/A- ASSET PURCHASE AGREEMENT, Investore Presentation
Regulatory Filings
2024-03-28 English
FORM 8-K/A- ASSET PURCHASE AGREEMENT, Investore Presentation
Report Publication Announcement
2024-03-28 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-03-18 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Regulatory Filings
2024-03-18 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-03-15 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Report Publication Announcement
2024-03-15 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-03-14 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Report Publication Announcement
2024-03-14 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-03-13 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Report Publication Announcement
2024-03-13 English
FORM 10K FOR 31.12.23
Regulatory Filings
2024-03-08 Hebrew (modern)
FORM 10K FOR 31.12.23
Report Publication Announcement
2024-03-08 English
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
Earnings Release Q1 2024
2024-03-05 English
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
Report Publication Announcement
2024-03-05 English
Schedule 14A Notice Annual Meeting of stockholders be held on Thursday, March 28, 2024.Proxy
Proxy Solicitation & Information Statement
2024-03-02 English
Schedule 14A Notice Annual Meeting of stockholders be held on Thursday, March 28, 2024.Proxy
Proxy Solicitation & Information Statement
2024-03-02 English
Annual Report on Form 10-K
Annual Report FY 2023
2024-03-02 English
Annual Report on Form 10-K
Report Publication Announcement
2024-03-02 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2024-02-29 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Report Publication Announcement
2024-02-29 English
FORM 8-K- Fourth Quarter 2023 Business Highlights and Financial Results
Earnings Release Q4 2023
2024-02-28 English
FORM 8-K- Fourth Quarter 2023 Business Highlights and Financial Results
Report Publication Announcement
2024-02-28 English
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial
Earnings Release Q4 2023
2024-02-28 English
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial
Report Publication Announcement
2024-02-28 English
Immediate Report
Earnings Release Q4 2023
2024-02-23 English
Immediate Report
Report Publication Announcement
2024-02-23 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost
Director's Dealing
2024-02-22 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost
Report Publication Announcement
2024-02-22 English
Schedule 14A - Preliminary Proxy Statement
Proxy Solicitation & Information Statement
2024-02-17 English
Schedule 14A - Preliminary Proxy Statement
Proxy Solicitation & Information Statement
2024-02-17 English
Alexis Borisy informed the Board that he does not intend to stand for reelection at the Company’s 2024 Annual Meeting of Stockholders.
Board/Management Information
2024-02-11 English
Alexis Borisy informed the Board that he does not intend to stand for reelection at the Company’s 2024 Annual Meeting of Stockholders.
Board/Management Information
2024-02-11 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES -Phillip Frost
Director's Dealing
2024-02-08 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES -Phillip Frost
Report Publication Announcement
2024-02-08 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Richard M. Krasno, Ph.D
Director's Dealing
2024-01-29 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Richard M. Krasno, Ph.D
Regulatory Filings
2024-01-29 English
SCHEDULE 13D/A-Hsu Gamma Investments, LP
Major Shareholding Notification
2024-01-25 English
SCHEDULE 13D/A-Hsu Gamma Investments, LP
Regulatory Filings
2024-01-25 English
SCHEDULE 13D/A-Frost Gamma Investments Trust
Major Shareholding Notification
2024-01-25 English
SCHEDULE 13D/A-Frost Gamma Investments Trust
Major Shareholding Notification
2024-01-25 English
terminated its share lending agreement entered into with Jefferies Capital Services, LLC
Transaction in Own Shares
2024-01-25 English
terminated its share lending agreement entered into with Jefferies Capital Services, LLC
Report Publication Announcement
2024-01-25 English
SCHEDULE 13D/A
Major Shareholding Notification
2024-01-22 English
SCHEDULE 13D/A
Major Shareholding Notification
2024-01-22 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-01-20 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Report Publication Announcement
2024-01-20 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Phillip Frost, M.D., ET AL
Director's Dealing
2024-01-20 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Phillip Frost, M.D., ET AL
Report Publication Announcement
2024-01-20 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Jane H. Hsiao, Ph.D
Director's Dealing
2024-01-18 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Jane H. Hsiao, Ph.D
Report Publication Announcement
2024-01-18 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-01-17 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2024-01-17 English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Phillip Frost, M.D., ET AL
Director's Dealing
2024-01-14 English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Phillip Frost, M.D., ET AL
Report Publication Announcement
2024-01-14 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Gary J. Nabel,
Director's Dealing
2024-01-11 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Gary J. Nabel,
Regulatory Filings
2024-01-11 English
Completed its previously announced private offering of $230.0 million aggregate principal amount of its 3.75% Convertible Senior Notes due 2029
Regulatory Filings
2024-01-10 English
Completed its previously announced private offering of $230.0 million aggregate principal amount of its 3.75% Convertible Senior Notes due 2029
Report Publication Announcement
2024-01-10 English
OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Regulatory Filings
2024-01-08 English
OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Report Publication Announcement
2024-01-08 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-FORM 4
Director's Dealing
2024-01-08 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-FORM 4
Regulatory Filings
2024-01-08 English
CHANGES IN BENEFICIAL OWNERSHIP-FORM 4-Phillip Frost, M.D., ET AL
Director's Dealing
2024-01-08 English
CHANGES IN BENEFICIAL OWNERSHIP-FORM 4-Phillip Frost, M.D., ET AL
Report Publication Announcement
2024-01-08 English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Elias Zerhouni, M.D.
Director's Dealing
2024-01-06 English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Elias Zerhouni, M.D.
Director's Dealing
2024-01-06 English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Steve D. Rubin
Director's Dealing
2024-01-06 English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Steve D. Rubin
Director's Dealing
2024-01-06 English
CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-FORM 4- Richard C. Pfenniger, Jr
Director's Dealing
2024-01-06 English
CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-FORM 4- Richard C. Pfenniger, Jr
Director's Dealing
2024-01-06 English
CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- FORM 4- John A. Paganelli
Director's Dealing
2024-01-06 English
CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- FORM 4- John A. Paganelli
Director's Dealing
2024-01-06 English
Pricing of Private Offering of $200 Million Convertible
Regulatory Filings
2024-01-05 English
Pricing of Private Offering of $200 Million Convertible
Regulatory Filings
2024-01-05 English
Presentation-January 2024;Announces Private Offering of Convertible Senior Notes Due 2029
Investor Presentation
2024-01-04 English
Presentation-January 2024;Announces Private Offering of Convertible Senior Notes Due 2029
Regulatory Filings
2024-01-04 English